search
Back to results

Study to Compare the Pharmacokinetics of Daily Administration of Tricaprilin on Ketone Body Production

Primary Purpose

Alzheimer Disease

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Tricaprilin
Sponsored by
Cerecin
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Alzheimer Disease

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Healthy, adult, males or females, age 50 years and above, at Screening.
  2. Subject must be in reasonably good health as determined by the investigator based on a detailed medical history, full physical examination (including blood pressure and pulse rate measurement), 12 lead ECG and clinical laboratory tests. Subjects with mild, chronic, stable disease (e.g., controlled hypertension, Type 2 diabetes, etc) will be permitted to enrol.
  3. Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at Screening.
  4. Agrees to comply with study procedures including the confinement period of 28 days.
  5. Subject is able and willing to consume a prescribed full breakfast, lunch and dinner while confined in the CRU. Subject does not have specific dietary requirements (vegetarian, vegan, lactose-free, low-fat, etc.).
  6. Subject is not consuming a ketogenic diet (defined by consumption of < 50 gm carbohydrates per day).
  7. A non vasectomized male subject must agree to use a condom or abstain from sexual intercourse during the study and for 90 days following last dose of AC-SD 03. No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to Screening. A subject who has been vasectomized less than 4 months prior to Screening must follow the same restrictions as a non vasectomized male.
  8. Female subjects must be either surgically sterile or 2 or more years post-menopause.
  9. Has given voluntary, written informed consent to participate in the study.

Exclusion Criteria:

  1. History or presence of alcoholism or substance abuse disorder within the last year.
  2. Positive urine drug screen at Screening or Check-In.
  3. Subject is currently actively using MCTs, ketone esters, or other ketogenic products or is following a ketogenic diet.
  4. Clinically significant abnormal laboratory results at Screening that in the opinion of the PI preclude participating in this study
  5. Participation in another clinical trial within 30 days prior to Check-In.
  6. Subject has a known allergy to the study drug's active or inactive ingredients.
  7. Subject has been following a ketogenic diet (or other diet incompatible with the on-study diet), in the opinion of the investigator.
  8. Unable to refrain from, or anticipates the use of drugs other than allowed products, including prescription and non-prescription medications, beginning 14 days prior to the first dose and throughout the study.

    1. Allowed medications include anti-hypertensive agents, statins, aspirin in a dose of 100 mg or less per day for prophylaxis.
    2. Paracetamol (acetaminophen), up to 4 g per 24 hour period, or ibuprofen (up to 1200 mg per 24-hour period) may be permitted during the study.
    3. Herbal remedies and vitamin supplements are permitted in usual doses (not hyper supplementation) so long as subject has been on stable amounts for at least 6 weeks.
    4. Agents being taken to improve memory or cognition are not allowed, whether herbal, 'natural' or pharmaceutical.
  9. Subject is known HIV, HBV or HCV positive, or has a positive test at Screening.
  10. Any other condition which, in the investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject.

Sites / Locations

  • Celerion

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

AC-SD-03

Arm Description

Study drug administered concurrently with a standard meal

Outcomes

Primary Outcome Measures

Safety and tolerability of multiple-dose administrations of tricaprilin formulated as AC-SD-03 administered using a titration scheme in healthy older volunteers
TEAE incidence rate

Secondary Outcome Measures

Pharmacokinetics (PK) parameters of Total Ketones levels after multiple dose of AC-SD-03 using AUC(0-t)
AUC(0-t) will be calculated from PK concentrations of Total Ketones (B-hydroxybutyrate and Acetoacetate) Levels. AUC (0-t) = Area under the concentration-time curve from 0 to last quantifiable concentration. Summary statistics will be generated for each PK parameter.
Pharmacokinetics (PK) parameters of Total Ketones levels after multiple dose of AC-SD-03 using Cmax
Cmax will be calculated from PK concentrations of Total Ketones (B-hydroxybutyrate and Acetoacetate) Levels. Cmax = Cmax is maximum concentration, determined directly from individual concentration-time data.Summary statistics will be generated for each PK parameter.

Full Information

First Posted
February 12, 2020
Last Updated
July 7, 2020
Sponsor
Cerecin
search

1. Study Identification

Unique Protocol Identification Number
NCT04268953
Brief Title
Study to Compare the Pharmacokinetics of Daily Administration of Tricaprilin on Ketone Body Production
Official Title
A Phase 1, Single-centre, Multiple-dose, Open-label Study to Assess the Safety, Tolerability, and Pharmacokinetics of the AC-SD-03 Formulation of Tricaprilin in Healthy Older Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
July 2020
Overall Recruitment Status
Completed
Study Start Date
February 27, 2020 (Actual)
Primary Completion Date
March 26, 2020 (Actual)
Study Completion Date
May 1, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cerecin

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a Phase I, single center, open label, multiple dose, pharmacokinetic (PK) study recruiting healthy older subjects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimer Disease

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
AC-SD-03
Arm Type
Experimental
Arm Description
Study drug administered concurrently with a standard meal
Intervention Type
Drug
Intervention Name(s)
Tricaprilin
Intervention Description
Tricaprilin formulated as AC-SD-03 mixed in 300mL water
Primary Outcome Measure Information:
Title
Safety and tolerability of multiple-dose administrations of tricaprilin formulated as AC-SD-03 administered using a titration scheme in healthy older volunteers
Description
TEAE incidence rate
Time Frame
32 days
Secondary Outcome Measure Information:
Title
Pharmacokinetics (PK) parameters of Total Ketones levels after multiple dose of AC-SD-03 using AUC(0-t)
Description
AUC(0-t) will be calculated from PK concentrations of Total Ketones (B-hydroxybutyrate and Acetoacetate) Levels. AUC (0-t) = Area under the concentration-time curve from 0 to last quantifiable concentration. Summary statistics will be generated for each PK parameter.
Time Frame
28 days
Title
Pharmacokinetics (PK) parameters of Total Ketones levels after multiple dose of AC-SD-03 using Cmax
Description
Cmax will be calculated from PK concentrations of Total Ketones (B-hydroxybutyrate and Acetoacetate) Levels. Cmax = Cmax is maximum concentration, determined directly from individual concentration-time data.Summary statistics will be generated for each PK parameter.
Time Frame
28 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy, adult, males or females, age 50 years and above, at Screening. Subject must be in reasonably good health as determined by the investigator based on a detailed medical history, full physical examination (including blood pressure and pulse rate measurement), 12 lead ECG and clinical laboratory tests. Subjects with mild, chronic, stable disease (e.g., controlled hypertension, Type 2 diabetes, etc) will be permitted to enrol. Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at Screening. Agrees to comply with study procedures including the confinement period of 28 days. Subject is able and willing to consume a prescribed full breakfast, lunch and dinner while confined in the CRU. Subject does not have specific dietary requirements (vegetarian, vegan, lactose-free, low-fat, etc.). Subject is not consuming a ketogenic diet (defined by consumption of < 50 gm carbohydrates per day). A non vasectomized male subject must agree to use a condom or abstain from sexual intercourse during the study and for 90 days following last dose of AC-SD 03. No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to Screening. A subject who has been vasectomized less than 4 months prior to Screening must follow the same restrictions as a non vasectomized male. Female subjects must be either surgically sterile or 2 or more years post-menopause. Has given voluntary, written informed consent to participate in the study. Exclusion Criteria: History or presence of alcoholism or substance abuse disorder within the last year. Positive urine drug screen at Screening or Check-In. Subject is currently actively using MCTs, ketone esters, or other ketogenic products or is following a ketogenic diet. Clinically significant abnormal laboratory results at Screening that in the opinion of the PI preclude participating in this study Participation in another clinical trial within 30 days prior to Check-In. Subject has a known allergy to the study drug's active or inactive ingredients. Subject has been following a ketogenic diet (or other diet incompatible with the on-study diet), in the opinion of the investigator. Unable to refrain from, or anticipates the use of drugs other than allowed products, including prescription and non-prescription medications, beginning 14 days prior to the first dose and throughout the study. Allowed medications include anti-hypertensive agents, statins, aspirin in a dose of 100 mg or less per day for prophylaxis. Paracetamol (acetaminophen), up to 4 g per 24 hour period, or ibuprofen (up to 1200 mg per 24-hour period) may be permitted during the study. Herbal remedies and vitamin supplements are permitted in usual doses (not hyper supplementation) so long as subject has been on stable amounts for at least 6 weeks. Agents being taken to improve memory or cognition are not allowed, whether herbal, 'natural' or pharmaceutical. Subject is known HIV, HBV or HCV positive, or has a positive test at Screening. Any other condition which, in the investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject.
Facility Information:
Facility Name
Celerion
City
Tempe
State/Province
Arizona
ZIP/Postal Code
85283
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Study to Compare the Pharmacokinetics of Daily Administration of Tricaprilin on Ketone Body Production

We'll reach out to this number within 24 hrs